Cardiac Science Reports Q2 Revenue; Resumes AED...( ...),Health

BOTHELL, Wash., Aug. 10 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, today announced that revenue for the second quarter ended June 30, 2009, was $36.1 million, a result that was adversely impacted by a decision to withhold $3 million in AED shipments during the quarter in accordance with the Company's internal quality procedures. The Company also announced that shipments of AEDs have resumed.

In addition to the impact from withheld AED shipments, second quarter results reflect a contraction in Japanese AED revenue and continued weakness in the market for healthcare capital equipment.

Cardiac monitoring revenue was $14.8 million and defibrillation products revenue was $16.9 million for the second quarter of 2009. As expected, AED sales in Japan were $9.1 million less than in the prior year quarter, primarily due to market weakness and a pending competing AED product introduction by the Company's current distribution partner. North American AED sales were down 32% compared to the prior year period, due to the withheld AED shipments and the effects of a weaker economy. Cardiac monitoring revenue decreased 5% compared to the prior year period, driven by slowed buying patterns in the hospital and physician office markets. However, second quarter 2009 cardiac monitoring revenue was up 20% sequentially ov
'/>"/>